| 产品描述: | Pomotrelvir is a selective, competitive, orally active covalent inhibitor of the SARS-CoV-2 main protease (Mpro), with an IC50 of 24 nM for wild-type SARS-CoV-2 Mpro. Pomotrelvir inhibits viral polyprotein processing, thereby preventing viral replication. Pomotrelvir has shown broad antiviral activity against multiple SARS-CoV-2 variants (including Omicron) in cell-based experiments, and has an additive effect when combined with nucleoside analogs that target viral RNA synthesis. Pomotrelvir is primarily used for the research and development of COVID-19 antiviral drugs, especially for infections caused by SARS-CoV-2 and its variants. |
| 靶点: |
SARS-CoV-2 (Mpro:24 nM (IC50) |
| 体内研究: |
酶活性测定实验:Pomotrelvir 竞争性抑制 SARS-CoV-2 Mpro,Ki 为 2.7 nM;且对其他人类冠状病毒 (CoV-229E、CoV-OC43 等) 的 Mpro 也有抑制作用,IC50 为 61-379 nM。 细胞感染实验:Pomotrelvir (23-36 nM;48 h) 在 iPS-AT2、A549-hACE2 和 Huh7 细胞的 SARS-CoV-2 感染或复制实验中,显著抑制病毒复制,EC50 值为 23-36 nM,对 Omicron 等临床分离株有效。 交叉耐药性实验:Pomotrelvir 对携带 Nirmatrelvir 耐药突变 (如 E166V、H172Y) 的 Mpro 抑制活性显著下降,部分突变 (如 L50F、T21I) 不影响其抑制效果。 结合特异性实验:Pomotrelvir (100 μM) 在人类蛋白酶抑制实验中,对 caspase-2、Chymotrypsin C 等无抑制作用,显示出对 SARS-CoV-2 Mpro 的高选择性。 |
| 保存条件: |
-80°C 6个月; -20°C 1个月,避光,氮气保存 |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.193 ml |
10.966 ml |
21.933 ml |
| 5 mM |
0.439 ml |
2.193 ml |
4.387 ml |
| 10 mM |
0.219 ml |
1.097 ml |
2.193 ml |
| 50 mM |
0.044 ml |
0.219 ml |
0.439 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |